BVS logo

BIOVENTUS INC - A

BVSNASDAQ
πŸ† #2367 by market capUS Equity
$212.87β–² $12.96 (+6.09%)
Simulated price
πŸ””
Track BVS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 6.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.18B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+3.1%
Slowing
πŸ“ŠGross Margin
68.7%
High
πŸ’΅FCF Margin
16.2%
Healthy
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
64
Fair
No chart data available for BVS.

Trading Snapshot

Day Range
$210.35 – $216.40
52-Week Range
$6.26 – $15.89
Volume
$2.81B
Avg Volume
$1.90B
Shares Outstanding
67.8M
Next Earnings
Oct 29, 2026

Fundamentals Snapshot

Annual Revenue
$568M
Last Q Revenue
$153M
P/E Ratio
21.6
P/S Ratio
2.0x
EPS (TTM)
$0.78
Dividend Yield
β€”
Dilution (1yr)
+5.3%

Why Investors Own BVS

  • βœ“High-growth profile β€” revenue up +17.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 51% gross margin and 26% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BVS logo

BIOVENTUS INC - A

BVS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$568Mβ–Ό βˆ’0.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.3%β–Ό βˆ’0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$59Mβ–Ό βˆ’588.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$71Mβ–² +89.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
68.9Mβ–² +5.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$260Mβ–² +$34M YoY
StockOtter Β· stockotter.space

About BIOVENTUS INC - A

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$237.03
β–² +11.4% Upside
High Target$290.72
Low Target$201.58
Based on 22 analysts

Latest News & Updates